An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia (NCT06924255)
An 8-week Open-label, Multicenter Randomized Study of Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment to Assess the Safety, Tolerability, and Efficacy in Participants With DSM-5 Schizophrenia
🩺 Plain-English Summary (8th-Grade Level)
The study design is a de-escalation of current atypical AP treatment to X/T at a maintenance dose of X/T established either at 100 mg xanomeline/20 mg trospium chloride BID (total daily dose 200 mg xanomeline/40 mg trospium chloride) or 125 mg xanomeline/30 mg trospium chloride BID (total daily dose 250 mg xanomeline/60 mg trospium chloride) based on participants' clinical response and/or tolerability. While the package insert for X/T provides guidance for clinicians on dosing, this study is designed to assess how transitioning will occur in the "real world" situation.
Who can join: Review the eligibility criteria below.
Location: CenExel CIT LA — Bellflower, California
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- CenExel CIT LA — Bellflower, California
- CenExel CNS - Garden Grove — Garden Grove, California
- CenExel CIT IE — Riverside, California
- CenExel CNS - Torrance — Torrance, California
- CenExel RCA — Hollywood, Florida
- CenExel CBH — Gaithersburg, Maryland
- CenExel HRI Marlton — Marlton, New Jersey
📞 Contact the Study Coordinator
Phone: (866) 478-8391
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Schizophrenia Disorders
- Visual Perception in Schizophrenia — Rochester, New York
- Brain Stimulation to the Hippocampus in Schizophrenia — Stanford, California
- White Matter Plasticity in Schizophrenia — Catonsville, Maryland
- Volatility in Paranoia (VIP) Trial: An RCT of Changes in Volatility With Psychotherapy — Nashville, Tennessee
- Randomized Clinical Trial of iTEST: A Blended Intervention Targeting Introspective Accuracy — San Diego, California
Explore by condition: All Schizophrenia Disorders clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.